Mitsubishi UFJ Asset Management Co. Ltd. Grows Stake in Edwards Lifesciences Corporation $EW

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 5.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,228,567 shares of the medical research company’s stock after buying an additional 63,266 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $104,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth $25,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $28,000. Hantz Financial Services Inc. boosted its stake in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares during the last quarter. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $29,000. Finally, Rakuten Securities Inc. boosted its stake in shares of Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 0.5%

EW opened at $82.75 on Friday. The stock has a market cap of $47.71 billion, a price-to-earnings ratio of 44.01, a P/E/G ratio of 2.09 and a beta of 0.87. The stock’s 50 day moving average price is $82.16 and its 200-day moving average price is $82.74. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent research reports. UBS Group reaffirmed a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Finally, Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.65.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. This represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,816,861.34. The trade was a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 88,096 shares of company stock valued at $7,288,799. 0.31% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.